Department of Neurology, University of Maryland School of Medicine, Baltimore, MD, USA.
Department of Neurology, University of Maryland School of Medicine, Baltimore, MD, USA; Department of Neurosciences, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Clin Immunol. 2020 Jan;210:108297. doi: 10.1016/j.clim.2019.108297. Epub 2019 Nov 5.
In this study, we investigated the role of JNK and phospho-Bcl-2 as possible biomarkers of multiple sclerosis (MS) relapse and of glatiramer acetate (GA) therapeutic response in relapsing-remitting MS patients. We enrolled a cohort of 15 GA-treated patients and measured the expression of JNK1, JNK2, phospho-JNK and phospho-Bcl-2 through Western blotting of lysates from peripheral blood mononuclear cells collected at 0, 3, 6, and 12 months after initiating GA therapy. We found significantly higher levels of JNK1 p54 and JNK2 p54 and significantly lower levels of p-Bcl-2 in relapse patients and in GA non-responders. By using receiver operating characteristic analysis, we found that the probability of accurately detecting relapse and response to GA was: 92% and 75.5%, respectively, for JNK1 p54 and 86% and 94.6%, respectively, for p-Bcl-2. Our data suggest that JNK1 and p-Bcl-2 could serve as potential biomarkers for MS relapse and the therapeutic response to GA.
在这项研究中，我们研究了 JNK 和磷酸化 Bcl-2 作为多发性硬化症（MS）复发的可能生物标志物，以及作为复发缓解型 MS 患者用 GA 治疗应答的可能生物标志物。我们招募了一组 15 名 GA 治疗患者，通过 Western blot 分析外周血单个核细胞裂解物，测量了 JNK1、JNK2、磷酸化 JNK 和磷酸化 Bcl-2 的表达，这些样本取自 GA 治疗开始后 0、3、6 和 12 个月。我们发现复发患者和 GA 无应答者的 JNK1 p54 和 JNK2 p54 水平显著升高，p-Bcl-2 水平显著降低。通过使用受试者工作特征分析，我们发现 JNK1 p54 准确检测复发和 GA 应答的概率分别为：92%和 75.5%，p-Bcl-2 的概率分别为：86%和 94.6%。我们的数据表明 JNK1 和 p-Bcl-2 可作为 MS 复发和 GA 治疗应答的潜在生物标志物。
